GOLDENPOWER (03919) completed the issuance of 6.48 million subscribed shares.
Golden Power Group (03919) announced that it has completed the implementation on May 19, 2026. According to the terms and conditions of the subscription agreement, the subscriber has subscribed and the company has issued and issued 6.48 million subscription shares at a subscription price of HK$1.20 per share, equivalent to: the existing issued share capital of the Company before completion is approximately 20%; and the issued share capital of the Company after the subscription shares are issued and issued is approximately 16.7%.
GOLDENPOWER (03919) announced that the subscription agreement has been completed on May 19, 2026. In accordance with the terms and conditions of the subscription agreement, the subscriber has subscribed and the company has issued and distributed 6.48 million subscription shares at a price of HK$1.20 per share, equivalent to approximately 20% of the existing issued share capital of the company before completion; and approximately 16.7% of the issued share capital of the company after the issuance and distribution of the subscription shares.
Related Articles
DUALITYBIO-B (09606) plans to repurchase up to $40 million worth of shares, and founder Zhu Zhongyuan plans to increase his shareholding by no more than $5 million.
XD INC (02400) repurchased 3.136 million shares cancelled on May 19th.
IMMUNEONCO-B (01541): The first patient has been dosed in the phase II randomized and placebo-controlled trial of IMM0306 for the treatment of SLE.
DUALITYBIO-B (09606) plans to repurchase up to $40 million worth of shares, and founder Zhu Zhongyuan plans to increase his shareholding by no more than $5 million.
XD INC (02400) repurchased 3.136 million shares cancelled on May 19th.
IMMUNEONCO-B (01541): The first patient has been dosed in the phase II randomized and placebo-controlled trial of IMM0306 for the treatment of SLE.
